TABLE 3.
Demographic characteristics of our assembled PTLD cohort (n = 305 patients)
| Variable | Category | N (%) |
|---|---|---|
| Transplant below age 1 | Yes | 26/305 (8.52%) |
| Pediatric patient (0–18 y) | Yes | 129/305 (42.3%) |
| Gender | Male | 178/305 (58.36%) |
| Female | 127/305 (41.64%) | |
| Race | Asian | 13/305 (4.26%) |
| Other | 20/305 (6.56%) | |
| Caucasian | 234/305 (76.72%) | |
| Unknown | 7/305 (2.3%) | |
| Black | 28/305 (9.18%) | |
| Mixed | 3/305 (0.98%) | |
| Transplant organ | Heart | 71/304 (23.28%) |
| Hematopoietic stem cell | 18/305 (5.9%) | |
| Lung | 61/305 (20%) | |
| Kidney/Renal | 74/305 (24.26%) | |
| Multi-organ Transplant | 22/305 (7.21%) | |
| Liver | 49/305 (16.07%) | |
| Intestine | 9/305 (2.95%) | |
| Other | 1/305 (0.33%) | |
| Donor CMV status | Positive | 64/146 (43.84%) |
| Negative | 58/146 (39.73%) | |
| Unknown | 24/146 (16.44%) | |
| Donor EBV status | Positive | 56/143 (39.16%) |
| Negative | 13/143 (9.09%) | |
| Unknown | 74/143 (51.75%) | |
| Recipient CMV status | Positive | 62/235 (26.38%) |
| Negative | 95/235 (40.43%) | |
| Unknown | 78/235 (33.19%) | |
| Recipient EBV status | Positive | 51/231 (22.08%) |
| Negative | 71/231 (30.74%) | |
| Unknown | 109/231 (47.19%) | |
| Locations of PTLD | Lymph node | 160/305 (52.46%) |
| GI tract | 92/305 (30.16%) | |
| Kidney | 15/305 (4.92%) | |
| Liver | 34/305 (11.15%) | |
| CNS | 12/305 (3.93%) | |
| Disseminated | 28/305 (9.18%) | |
| Bone marrow | 10/305 (3.28%) | |
| Lung | 64/305 (20.98%) | |
| Other | 96/305 (31.48%) | |
| Unknown | 6/305 (1.97%) | |
| Was Rituximab given to treat PTLD? | Yes | 211/295 (71.53%) |
| Did a second PTLD event occur after complete remission of the first PTLD event at any point in time during follow-up? | Yes | 36/236 (15.25%) |
| Is the recipient alive? | No | 210/305 (68.85%) |
| Yes | 88/305 (28.85%) | |
| Lost to follow up | 3/305 (0.98%) | |
| Unknown | 4/305 (1.31%) | |
| Cause of death | PTLD related cause | 114/209 (54.29%) |
| Unknown | 36/210 (17.14%) | |
| PTLD unrelated cause | 59/210 (28.1%) | |
| Unknown | 1/210 (0.48%) | |
| Was systemic chemotherapy given to treat PTLD? | No chemotherapy used | 114/305 (37.38%) |
| New chemotherapy start | 156/305 (51.15%) | |
| Unknown | 33/305 (10.82%) | |
| Change to chemotherapy | 2/305 (0.66%) | |
| Years from transplant to initial PTLD diagnosis | Early PTLD (≤1 y) | 100/305 (32.79%) |
| Late PTLD (>1 y) | 205/305 (67.21%) |
CMV, Cytomegalovirus; CNS, Central nervous system; EBV, Epstein-Barr virus ; PTLDs, post-transplant lymphoproliferative disorders.